Martha Chekenya

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2014-2023
Publications (10 Years): 9

Top Venues

PloS one

Cancers

Neuro-oncology advances

Journal of immunology (Baltimore, Md. : 1950)

University of Bergen

King's College London (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Bergen Aug 01 2013

Norway

Professor :: Biomedicine/clinical Dentistry

University of Bergen Jan 01 2011 - Dec 13 2013

Norway

Senior Scientist :: Biomedicine

University of Bergen Jan 01 2008 - Dec 31 2010

Norway

Senior scientist/group leader :: Biomedicine

University of Bergen

Norway

Post doctoral fellow :: Biomedicine

Education History

King's College London

United Kingdom

PHD :: Neuropathology

Institute of Pyschiatry/Kings College, University of London

United Kingdom

MSC :: Neuroscience

University of Westminster

United Kingdom

BSC :: Psychology

Publications

Hanne Blakstad, Jorunn Brekke, Mohummad Aminur Rahman, Victoria Smith Arnesen, Hrvoje Miletic, Petter Brandal, Stein Atle Lie, Martha Chekenya, Dorota Goplen
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions. PloS one 18 (2) (2023)
Hanne Blakstad, Jorunn Brekke, Mohummad Aminur Rahman, Victoria Smith Arnesen, Hrvoje Miletic, Petter Brandal, Stein Atle Lie, Martha Chekenya, Dorota Goplen
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions. PloS one 18 (2) (2023)
Marianne H Hannisdal, Dorota Goplen, Saruar Alam, Judit Haasz, Leif Oltedal, Mohummad A Rahman, Cecilie Brekke Rygh, Stein Atle Lie, Arvid Lundervold, Martha Chekenya
Feasibility of deep learning-based tumor segmentation for target delineation and response assessment in grade-4 glioma using multi-parametric MRI. Neuro-oncology advances 5 (1) (2023)
Hanne Blakstad, Jorunn Brekke, Mohummad Aminur Rahman, Victoria Smith Arnesen, Hrvoje Miletic, Petter Brandal, Stein Atle Lie, Martha Chekenya, Dorota Goplen
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions. PloS one 18 (2) (2023)
Marianne H Hannisdal, Dorota Goplen, Saruar Alam, Judit Haasz, Leif Oltedal, Mohummad A Rahman, Cecilie Brekke Rygh, Stein Atle Lie, Arvid Lundervold, Martha Chekenya
Feasibility of deep learning-based tumor segmentation for target delineation and response assessment in grade-4 glioma using multi-parametric MRI. Neuro-oncology advances 5 (1) (2023)
Hanne Blakstad, Jorunn Brekke, Mohummad Aminur Rahman, Victoria Smith Arnesen, Hrvoje Miletic, Petter Brandal, Stein Atle Lie, Martha Chekenya, Dorota Goplen
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions. PloS one 18 (2) (2023)
Victoria Smith Arnesen, Andrea Gras Navarro, Martha Chekenya
Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy. Cancers 13 (19) (2021)
Mohummad A Rahman, Jorunn Brekke, Victoria Arnesen, Marianne H Hannisdal, Andrea G Navarro, Andreas Waha, Lars Herfindal, Cecilie B Rygh, Eirik Bratland, Petter Brandal, Judit Haasz, Leif Oltedal, Hrvoje Miletic, Arvid Lundervold, Stein A Lie, Dorota Goplen, Martha Chekenya
Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study. Immunity, inflammation and disease 8 (3) (2020)
Andrea Gras Navarro, Heidi Espedal, Justin Vareecal Joseph, Laura Trachsel-Moncho, Marzieh Bahador, Bjørn Tore Gjertsen, Einar Klæboe Kristoffersen, Anne Simonsen, Hrvoje Miletic, Per Øyvind Enger, Mohummad Aminur Rahman, Martha Chekenya
Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival. Cancers 11 (7) (2019)
Andrea Gras Navarro, Justyna Kmiecik, Lina Leiss, Mateusz Zelkowski, Agnete Engelsen, Øystein Bruserud, Jacques Zimmer, Per Øyvind Enger, Martha Chekenya
NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival. Journal of immunology (Baltimore, Md. : 1950) 193 (12) (2014)

Martha Chekenya.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Martha Chekenya